Baltimore, Md. – Jhpiego has been recognized as a “Very High Performer” and a “Consistently High Performer” by Global Health 50/50 (GH5050) for the first time in its continued efforts to prioritize gender equality—both within the organization and in the global health sector broadly. In each of the previous three years, GH5050, an independent research
As global leaders gather at the World Health Assembly, Jhpiego has joined other global partners in signing onto a statement (see below) to raise awareness about the potential impact of a single-dose human papillomavirus (HPV) vaccine schedule for adolescents, ages 9-14. As the world rallies to recover from disruptions to immunization coverage due to COVID-19
A preventive malaria program led by Jhpiego receives high praise in an independent review for its community-focused, sustainable approach that has saved the lives of thousands of pregnant women. The Transforming Intermittent Preventive Treatment for Optimal Pregnancy (TIPTOP) project, operating over 5 years in four malaria-endemic, sub-Saharan African countries, introduced a community-based approach that contributed
